Anti-siglec-7 antibodies for the treatment of cancer
AssigneeAllakos Inc.
InventorsChristopher Bebbington, Wouter Korver, Nenad Tomasevic, Suzy El Bader, Kenneth Luehrsen
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions for the treatment of cancer using anti-Siglec7 antibodies.
Claims131
A method of inhibiting proliferation of tumor cells, the method comprising administering a therapeutically effective amount of an anti-Siglec-7 antibody to a patient that has cancer, wherein the patient has a primary tumor or metastatic lesion that comprises an elevated level of CD8+ infiltrating-T cells that express Siglec-7, and further, wherein the tumor or metastatic lesion comprises cancer cells that express sialylated Siglec-7 ligands.
An anti-Siglec-7 antibody that competes with an antibody having a variable heavy chain sequence of SEQ ID NO:
- 1 and a variable light chain sequence of SEQ ID NO:15 for binding to Siglec-7.
An anti-Siglec-7 antibody that blocks binding of ligand to Siglec-7 and competes with antibody QA79 produced from the hybridoma deposited under accession number ICLC PD99003 for binding to Siglec-7, but does not compete with antibody Z176 or antibody S7.7 for binding to Siglec-7.
An anti-Siglec-7 antibody that has internalization activity, does not block ligand binding to Siglec-7, and competes with antibody S7.7, but not with antibody QA79 or antibody Z176, for binding to Siglec-7.
An anti-Siglec-7 antibody has internalization activity, does not block ligand binding to Siglec-7, and competes with antibody Z176, but not with antibody QA79 or antibody S7.7 for binding to Siglec-7.
An anti-Siglec-7 antibody having a VH region that comprises at least one CDR, or at least two CDRs, of a VH region sequence set forth in FIG. 1.
An anti-Siglec-7 antibody having a VH region that comprises a CDR1, CDR2, and CDR3 of one of the heavy chain variable region sequences set forth in FIG. 1.
An anti-Siglec-7 antibody having a VL region that comprises at least one CDR, or at least two CDRs, of a VL region sequence set forth in FIG. 2.
An anti-Siglec-7 antibody having a VH region that comprises a CDR1, CDR2, and CDR3 of one of the light chain variable region sequences set forth in FIG. 2.
A method of identifying a patient that is a candidate for treatment with an anti-Siglec-7 antibody, the method comprising determining the proportion of CD8+ T cells that have infiltrated a tumor, or a metastatic lesion, that express Siglec-7.
A method of identifying a patient that has a tumor that is a candidate for treatment with an anti-Siglec-7 antibody, the method comprising determining that at least 10% of tumor-infiltrating CD8+ T cells in the tumor or a metastatic lesion, express Siglec-7.
A method of identifying a patient that has a tumor that is a candidate for treatment with an anti-Siglec-7 antibody, the method comprising determining the proportion of CD8+ infiltrating T cells in a tumor or metastatic lesion that express Siglec-7, wherein a patient that has a tumor or metastatic lesion in which at least 10% of infiltrating CD8+ T express Siglec-7 is a candidate for treatment with an anti-Siglec-7 antibody.
Dependencies are inferred from the claim text.